Current and emerging applications of 3D printing in medicine

CY Liaw, M Guvendiren - Biofabrication, 2017 - iopscience.iop.org
Abstract Three-dimensional (3D) printing enables the production of anatomically matched
and patient-specific devices and constructs with high tunability and complexity. It also allows …

Synthesis, properties, and applications of polylactic acid‐based polymers

H Ramezani Dana, F Ebrahimi - Polymer Engineering & …, 2023 - Wiley Online Library
Polylactic acid (PLA) is known as one of the greatest promising bioabsorbable and
compostable polyesters with the capability of high molecular weight synthesis. Lactic acid …

Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling

A Skardal, T Shupe, A Atala - Drug discovery today, 2016 - Elsevier
Highlights•Traditional drug screening model systems are inadequate.•Organoid-on-a-chip
platforms stand to significantly advance drug and toxicology screening.•A wide variety or …

Microfluidic organ-on-a-chip models of human liver tissue

E Moradi, S Jalili-Firoozinezhad, M Solati-Hashjin - Acta biomaterialia, 2020 - Elsevier
The liver is the largest internal organ of the body with complex microarchitecture and
function that plays critical roles in drug metabolism. Hepatotoxicity and drug-induced liver …

Poly lactic acid (PLA) polymers: from properties to biomedical applications

F Ebrahimi, H Ramezani Dana - International Journal of Polymeric …, 2022 - Taylor & Francis
Polylactic acid (PLA), one of the well-known bioabsorbable and compostable polyesters has
rapidly evolved into a competitive commodity material over the last decades. To provide …

Drug compound screening in single and integrated multi-organoid body-on-a-chip systems

A Skardal, J Aleman, S Forsythe, S Rajan… - …, 2020 - iopscience.iop.org
Current practices in drug development have led to therapeutic compounds being approved
for widespread use in humans, only to be later withdrawn due to unanticipated toxicity …

Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform

A Skardal, SV Murphy, M Devarasetty, I Mead… - Scientific reports, 2017 - nature.com
Many drugs have progressed through preclinical and clinical trials and have been available–
for years in some cases–before being recalled by the FDA for unanticipated toxicity in …

3D bioprinting for drug discovery and development in pharmaceutics

W Peng, P Datta, B Ayan, V Ozbolat, D Sosnoski… - Acta biomaterialia, 2017 - Elsevier
Successful launch of a commercial drug requires significant investment of time and financial
resources wherein late-stage failures become a reason for catastrophic failures in drug …

Optimization of collagen type I-hyaluronan hybrid bioink for 3D bioprinted liver microenvironments

A Mazzocchi, M Devarasetty, R Huntwork, S Soker… - …, 2018 - iopscience.iop.org
Current 3D printing of tissue is restricted by the use of biomaterials that do not recapitulate
the native properties of the extracellular matrix (ECM). These restrictions have thus far …

[HTML][HTML] Microfluidic platforms for cell cultures and investigations

ML Coluccio, G Perozziello, N Malara, E Parrotta… - Microelectronic …, 2019 - Elsevier
This review covers several aspects of microfluidic devices used for culturing and monitoring
of both adherent and non-adherent cells, including a multitude of applications. A comparison …